


FOR PTO-1449 (Modified)

LIST OF PATENTS AND PUBLICATIONS FOR APPLICANTS INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)



ATTY. DOCKET NO. 480.18-4 (HV)	SERIAL NO. 09/392,682
APPLICANT DIETER C. GRUENERT, ET AL	
FILING DATE September 9, 1999	GROUP 4632 1036

REFERENCE DESIGNATION		U.S. PATENT DOCUMENTS										DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
EXAMINER INITIAL																
<i>mf</i>	A	4	9	5	0	5	9	9				8/21/90	BERTLING	435	423 456	1/29/87

FOREIGN PATENT DOCUMENTS													
								DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
												YES	NO

OTHER		ART (Including Author, Title, Date, Pertinent Pages, Etc.)														
<i>mf</i>	O		ERIC J. SORSCHER et al, Gene Therapy for Cystic Fibrosis Using Cationic Liposome Mediated Gene Transfer: A Phase I Trial of Safety and Efficacy in the Nasal Airway, Human Gene Therapy, 5:1259-1277, October 1994.													
	P		JAMES M. WILSON et al, Gene Therapy of Cystic Fibrosis Lung Disease Using E1 Deleted Adenoviruses: A Phase I Trial, Human Gene Therapy, 5:501-519, 1994.													
	Q		NATASHA J. CAPLEN et al, Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis, Nature Medicine, Volume 1, Number 1, pp. 39-46, January 1995.													
	R		RICHARD M. BOUCHER et al, Gene Therapy for Cystic Fibrosis Using E1-Deleted Adenovirus: A Phase I Trial in the Nasal Cavity, Human Gene Therapy 5:615-639, 1994													
	S		MITCHELL J. GOLDMAN et al, Gene therapy in a xenograft model of cystic fibrosis lung corrects chloride transport more effectively than the sodium defect, Nature Genetics, Volume 9, pp. 126-131 February 1995.													
	T		JOE PALCA, The Promise of a Cure, Discover, pp 79-86, June 1994.													
	U		JOSEPH ZABNER et al, Adenovirus-Mediated Gene Transfer Transiently Corrects the Chloride Transport Defect in Nasal Epithelia of Patients with Cystic Fibrosis, Cell, Vol 75, pp 207-216, October 22, 1993													
	V		TERRENCE R. FLOTTE et al, An improved system for packaging recombinant adeno-associated virus vectors capable of in vivo transduction, Gene Therapy, 2, pp 29-37, 1995													
	W		J.A. Dodge, Gene therapy for cystic fibrosis, Nature Medicine, Volume 1, Number 3, pp 182, March 3, 1995													
	X		DEBORAH ERICKSON, Genes to Order, Scientific American, pp 112-114, June 1992													
	Y		JAMES M. WILSON, Vehicles for gene therapy, Nature, Vol 365, pp 691-692, October 21, 1993													

EXAMINER *mf Joel*

DATE CONSIDERED 12/27/2000

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Use several sheets if necessary)

480.18-1 (HV)

09/392,682

DIETER C. GRUENERT, ET AL

FILING DATE September 9, 1999

GROUP ~~1632~~ 1636

**EXAMINER
INITIAL**

DATE _____

NAME _____

CLASS

SUBCLASS

**FILING DATE
IF APPROPRIATE**

DATE _____

COUNTRY

CLASS

SUBCLASS

TRANSLATION

YES	NO
-----	----

ART (Including Author, Title, Date, Pertinent Pages, Etc.)
$$\mathbf{z}$$

ERIC ALTON & DUNCAN GEDDES, A mixed message for cystic fibrosis gene therapy, Nature Genetics, Volume 8, pp 8-9,
September 1994

AA

JAMES J. LOGAN et al, Cationic lipids for reporter gene and CFTR transfer to rat pulmonary epithelium, *Gene Therapy* 2, pp 38-49, 1995

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Attorney Docket No. 480.18-1 (HV)
U.S. Serial No. 08/487,799